Please assess the completion status of the following clinical trial:

Trial Title: The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas (DCLP3 Extension)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Successful completion of the original 6-month RCT within the prior 14 days~2. For females, not currently known to be pregnant. If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative urine pregnancy test will be required for all females of child-bearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.~3. For participants \<18 years old, living with one or more parent/legal guardian knowledgeable about emergency procedures for severe hypoglycemia and able to contact the participant in case of an emergency.~4. Willingness to not use a personal CGM for the duration of the study~5. Investigator has confidence that the participant can successfully operate all study devices and is capable of adhering to the protocol~6. Willingness to use only lispro (Humalog) or aspart (Novolog), and to use no other insulin during the study.~7. Willingness not to start any new non-insulin glucose-lowering agent during the course of the trial~Exclusion Criteria~1. Concurrent use of any non-insulin glucose-lowering agent other than metformin (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas).~2. Hemophilia or any other bleeding disorder~3. A condition, which in the opinion of the investigator or designee, would put the participant or study at risk~4. Participation in another pharmaceutical or device trial at the time of enrollment or during the study~5. Employed by, or having immediate family members employed by Tandem Diabetes Care, Inc., Dexcom, Inc., or TypeZero Technologies, LLC, or having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Closed Loop Control (CLC) (Type: EXPERIMENTAL): Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology \& Dexcom G6 Continuous Glucose Monitor (CGM) for 3 months.~Objective 1: This arm is participants who had 6 months of CLC in the primary trial (DCLP3 Pivotal Trial)~Objective 2: This arm is participants who had 6 months of sensor-augmented pump (SAP) in the primary trial (DCLP3 Pivotal Trial)~Objective 3: This arm is participants who had 3 months of CLC in the extension trial (DCLP3 Extension) will continue use of the Control-IQ Technology \& Dexcom G6 CGM until the product is commercially available.
- Predictive-Low Glucose Suspend (PLGS) (Type: ACTIVE_COMPARATOR): Participants randomized to Predictive-Low Glucose Suspend (PLGS) will use the t:slim X2 with Basal-IQ \& Dexcom G6 CGM for 3 months.~Objective 1: This arm is participants who had 6 months of PLGS in the primary trial (DCLP3 Pivotal Trial)~Objective 2: This arm is not applicable to objective 2~Objective 3: This arm is participants who had 3 months of PLGS in the extension trial (DCLP3 Extension) will continue use of the Control-IQ Technology \& Dexcom G6 CGM until the product is commercially available.

Based on this trial design, predict the completion outcome and termination type (if applicable).